RUNX1T1 Antibody, Biotin conjugated

說明書

中文名稱：

RUNX1T1兔多克隆抗體, Biotin偶聯
貨號：

CSB-PA726765HD01HU
規格：

￥880
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) RUNX1T1 Polyclonal antibody
Uniprot No.：

Q06455
基因名：

RUNX1T1
別名：

Acute myelogenous leukemia 1 translocation 1 cyclin D related antibody; Acute myelogenous leukemia 1 translocation 1 protein antibody; AML1 MTG8 antibody; AML1T1 antibody; CBFA2T1 antibody; CDR antibody; Core binding factor runt domain alpha subunit 2 translocated to 1 antibody; Core binding factor runt domain alpha subunit 2 translocated to 1 cyclin D related antibody; Cyclin D related antibody; Cyclin D related protein antibody; Cyclin-D-related protein antibody; Eight twenty one protein antibody; ETO antibody; ETO protein antibody; MGC2796 antibody; MTG 8 antibody; MTG 8b antibody; MTG8 antibody; MTG8 protein antibody; MTG8_HUMAN antibody; MTG8b antibody; Myeloid translocation gene on 8q22 antibody; Protein CBFA2T1 antibody; Protein ETO antibody; Protein MTG 8 antibody; Protein MTG8 antibody; Runt related transcription factor 1 translocated to 1 (cyclin D related) antibody; Runt related transcription factor 1 translocated to 1 antibody; Runt related transcription factor 1 translocated to 1 cyclin D related antibody; RUNX1 translocation partner 1 antibody; RUNX1T1 antibody; Zinc finger MYND domain containing protein 2 antibody; Zinc finger MYND domain-containing protein 2 antibody; ZMYND 2 antibody; ZMYND2 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Protein CBFA2T1 protein (416-525AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Biotin
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes. Can repress the expression of MMP7 in a ZBTB33-dependent manner. Can repress transactivation mediated by TCF12. Acts as a negative regulator of adipogenesis. The AML1-MTG8/ETO fusion protein frequently found in leukemic cells is involved in leukemogenesis and contributes to hematopoietic stem/progenitor cell self-renewal.
基因功能參考文獻：
1. RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation. Over 90% of the 175 patients who were in continuous complete remission had a >/=3-log reduction in RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a >/=4-log reduction at >/=12 months. PMID: 28166825
2. The data suggest that the tumor suppressor activity of both RUNX1t1 and TFF1 are mechanistically connected to CEBPB and that cross-regulation between CEBPB-RUNX1t1-TFF1 plays an important role in gastric carcinogenesis. PMID: 27522676
3. The role of RUNX1T1 in t(8;21) acute myeloid leukemia and miRNA expression regulation PMID: 28322996
4. Our data revealed a novel role for RUNX1T1 as a tumor-suppressor gene in colorectal cancer through modulation of multiple cellular pathways affecting the cell cycle, DNA damage, DNA replication, estrogen signaling, and drug resistance PMID: 27798886
5. A substantial fraction of AML1-ETO/p300 co-localization occurs near TSSs in promoter regions associated with transcriptionally active loci. PMID: 25928846
6. A reduction in KIT mRNA levels was also observed in AE-silenced cells, but silencing KIT expression reduced cell growth but did not induce apoptosis. PMID: 24727677
7. RUNX1T1 gene may participate in t(8;21)(q22;q22)-dependent leukemic transformation due to its multiple interactions in cell regulatory network particularly through synergistic or antagonistic effects in relation to activity of RUNX1-RUNX1T1 fusion gene. PMID: 24976338
8. Runx1t1 epigenetically regulates the proliferation and nitric oxide production of microglia. PMID: 24586690
9. The cooperative effect of the expression of mutated KIT and AML1-ETO oncogenes is crucial for selective toxic action of binase on malignant cells. PMID: 22101339
10. RUNX1T1 point mutation may be rare and passenger mutations in acute leukemias, lung and breast cancers PMID: 21571369
11. SMAD4 knockdown accelerated this re-silencing process, suggesting that normal TGF-beta signaling is essential for the maintenance of RunX1T1 expression PMID: 21540640
12. Data show that low RUNX1T1 expression was highly associated with hepatic metastases. PMID: 21499216
13. Elevated levels of AES mRNA and protein were confirmed in AML1/ETO-expressing leukemia cells, as well as in other acute myeloid leukemia specimens. PMID: 21245488
14. ETO nervy homology region (NHR) 3 domain-PKA(RIIalpha) protein interaction does not appear to significantly contribute to AML1-ETO's ability to induce leukemia. PMID: 20708017
15. The critical role for an evolutionary conserved GATA binding site in transcriptional regulation of the ETO gene in cells of erythroid/megakaryocytic potential. PMID: 20487545
16. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells. PMID: 20090777
17. no conclusive evidence as yet that the AML1/ETO chimeric gene is sufficient per se to induce leukemia. PMID: 11869944
18. Analysis of nuclear distribution of the AML1/ETO protein and its homology domains led to identification of domains in ETO responsible for intranuclear transport and subnuclear distribution of AML1/ETO. PMID: 11983111
19. 2 independent subnuclear targeting signals in the N- and C-terminal regions of ETO direct ETO to the same binding sites occupied by AML1ETO. This provides a molecular basis for aberrant subnuclear targeting of AML1ETO, the defect in t(8;21)-related AML. PMID: 12427969
20. ETO rearrangements leading to the AML1-ETO fusion gene are frequently the result of small hidden interstitial insertions. PMID: 12557226
21. Data identify ETO as a partner for Gfi-1 and Gfi-1B, and suggest that Gfi-1 proteins repress transcription through recruitment of histone deacetylase-containing complexes. PMID: 12874834
22. ETO is a bona fide corepressor that links the transcriptional pathogenesis of acute leukemias and B-cell lymphomas and offers a compelling target for transcriptional therapy of hematologic malignancies. PMID: 14551142
23. RT-PCR for the detection of AML1/ETO in children with acute non-lymphoid leukemia (ANLL) was quick, convenient and sensitive, and could be regarded as a useful method for the diagnosis and prognosis of ANLL. PMID: 14751048
24. cloning, expression, purification and crystallization of NHR3 domain PMID: 15295650
25. These findings suggest a central role of RUNX1-CBFA2T1 in the maintenance of the leukaemia. PMID: 15298716
26. N-CoR utilizes repression domains I and III for interaction and co-repression with ETO PMID: 15377655
27. DiffeRential expression of the ETO homologues suggests that they may have a potential role in hematopoietic differentiation. PMID: 15676213
28. Alternative splicing in the AML1-MTG8 fusion gene occurs in leukemia cell lines as well as in cells of leukemia paatients with a(8;21) translocation. PMID: 15723339
29. Translocations in acute myeloid leukemia (AML) is the t(8;21) is characterized by AML1-MTG8 (ETO) mutation. PMID: 16502583
30. AML1T1, an alternatively spliced isoform of the t(8;21) transcript, promotes leukemogenesis. PMID: 16892037
31. The leukemia-associated fusion protein AML1-ETO could aberrantly transactivate the EEN gene through an AML1 binding site. PMID: 16990610
32. As a result, we identified 14 unique proteins deregulated in AML1-ETO-carrying leukemic cells, including 3 up-regulated such as hairy and enhancer of split 5 (HES5) and 11 down-regulated such as MAT1 (menage a trois-1. PMID: 17058450
33. AML1/ETO participates in a protein complex with the RA receptor alpha (RARalpha) at RA regulatory regions on RARbeta2. PMID: 17244680
34. Loss of p21(WAF1) facilitates AML1-ETO-induced leukemogenesis. PMID: 17284535
35. Isoform AML1/ETO9a was correlated to acute myeloid leukemia-M2 subtype. PMID: 17649722
36. Our study suggests that KIT activating mutations in AML with t(8; 21) are associated with diminished CD 19 and positive CD56 expression on leukemic blasts and, thus, can be phenotypically distinguished from AML1-ETO leukemias PMID: 17875504
37. MTG8/ETO and Mtg16 (ETO2) associated with TCF4 PMID: 18039847
38. These results demonstrate that scl is an important mediator of the ability of AML1-ETO to reprogram hematopoietic cell fate decisions, suggesting that scl may be an important contributor to AML1-ETO-associated leukemia. PMID: 18156164
39. The interaction between SIN3B and ETO required an intact amino-terminus of ETO and the NHR2 domain. PMID: 18205948
40. Knockdown of TLE1 or TLE4 levels increased the rate of cell division of the AML1-ETO-expressing Kasumi-1 cell line, whereas forced expression of either TLE1 or TLE4 caused apoptosis and cell death. PMID: 18258796
41. ETO family member-mediated oligomerization and repression can be distinct events and that interaction between ETO family members and hSIN3B or N-CoR may not necessarily strengthen transcriptional repression. PMID: 18586123
42. the crucial role of the NHR4 domain in determination of cellular fate during AML1-ETO-associated leukemogenesis. PMID: 18952841
43. a major role for the functional interaction of AML1/ETO with AML1 and HEB in transcriptional regulation determined by the fusion protein. PMID: 19043539
44. Four copies of RUNX1T1 were found. PMID: 19100510
45. Data show that E proteins contain another conserved ETO-interacting region, termed DES, and that differential associations with AD1 and DES allow ETO to repress transcription through both chromatin-dependent and chromatin-independent mechanisms. PMID: 19289505
顯示更多

收起更多
相關疾病：

A chromosomal aberration involving RUNX1T1 is a cause of acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1/AML1.
亞細胞定位：

Nucleus. Note=Colocalizes with ATN1 in discrete nuclear dots.
蛋白家族：

CBFA2T family
組織特異性：

Most abundantly expressed in brain. Lower levels in lung, heart, testis and ovary.
數據庫鏈接：

HGNC: 1535

OMIM: 133435

KEGG: hsa:862

STRING: 9606.ENSP00000402257

UniGene: Hs.368431

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human